215 related articles for article (PubMed ID: 6305499)
1. Treatment of advanced non-small cell lung cancer with bisantrene.
Fuks JZ; Van Echo DA; Garbino C; Kasdorf H; Aisner J
Cancer Treat Rep; 1983 Jun; 67(6):597-8. PubMed ID: 6305499
[No Abstract] [Full Text] [Related]
2. Phase II clinical trial with bisantrene in patients with advanced refractory small cell lung cancer.
Myers JW; Von Hoff DD; Clark GM; Coltman CA
Cancer Treat Rep; 1984 Jun; 68(6):927-8. PubMed ID: 6329511
[No Abstract] [Full Text] [Related]
3. Phase II evaluation of bisantrene in patients with advanced non-small cell lung carcinoma.
Feld R; Evans WK; Shepherd FA; Deboer G; Ottema B
Cancer Treat Rep; 1985 Feb; 69(2):209-10. PubMed ID: 3971392
[TBL] [Abstract][Full Text] [Related]
4. Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial.
Kramer BS; Birch R; Gockerman JP; Greco A; Prestridge K
Cancer Treat Rep; 1986 Jun; 70(6):803-4. PubMed ID: 3015404
[No Abstract] [Full Text] [Related]
5. Phase II evaluation of bisantrene in patients with renal cell carcinoma.
Myers JW; Von Hoff DD; Coltman CA; Kuhn JG; Van Echo D; Rivkin S; Pocelinko R
Cancer Treat Rep; 1982 Oct; 66(10):1869-71. PubMed ID: 7127326
[No Abstract] [Full Text] [Related]
6. Bisantrene in non-small cell lung cancer: a phase II trial of the Cancer and Leukemia Group B.
Green MR; Vosika G; Propert KJ; Ware JH; Comis R
Cancer Treat Rep; 1986 Apr; 70(4):539-40. PubMed ID: 3698052
[No Abstract] [Full Text] [Related]
7. Phase II study on DON in patients with previously treated advanced lung cancer.
Eagan RT; Frytak S; Nichols WC; Creagan ET; Ingle JN
Cancer Treat Rep; 1982 Aug; 66(8):1665-6. PubMed ID: 6286122
[No Abstract] [Full Text] [Related]
8. Evaluation of an intermittent schedule of mitolactol in advanced non-small cell lung cancer.
Eagan RT; Frytak S; Nichols WC; Ingle JN; Creagan ET; Kvols LK; Coles DT
Cancer Treat Rep; 1981; 65(11-12):1099-1101. PubMed ID: 6271397
[No Abstract] [Full Text] [Related]
9. Phase II trial of 4-demethoxydaunorubicin in patients with non-small cell lung cancer.
Joss RA; Obrecht JP; Alberto P; Siegenthaler P; VanHelvoirt A; Cavalli F
Cancer Treat Rep; 1984 Mar; 68(3):563-4. PubMed ID: 6322990
[No Abstract] [Full Text] [Related]
10. Bisantrene, an active drug in patients with advanced breast cancer.
Osborne CK; Von Hoff DD; Cowan JD; Sandbach J
Cancer Treat Rep; 1984 Feb; 68(2):357-60. PubMed ID: 6697324
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of AMSA in lung cancer.
Samson MK; Fraile RJ; Baker LH; Cummings G; Talley RW
Cancer Treat Rep; 1981; 65(7-8):655-8. PubMed ID: 6265083
[TBL] [Abstract][Full Text] [Related]
12. Phase II evaluation of vindesine in non-small cell bronchogenic carcinoma.
Hutcheon AW; Palmer JB; Pratt MA; Clark RA
Cancer Treat Rep; 1983 Nov; 67(11):1041-2. PubMed ID: 6315231
[No Abstract] [Full Text] [Related]
13. Phase II evaluation of bisantrene in patients with advanced renal cell carcinoma.
Evans WK; Shepherd FA; Blackstein ME; Osoba D; Taylor D
Cancer Treat Rep; 1985 Jun; 69(6):727-8. PubMed ID: 4016779
[No Abstract] [Full Text] [Related]
14. Phase II trial of bisantrene in advanced epidermoid carcinoma of the head and neck.
Forastiere AA; Crain SM; Garbino C; Tipping SJ; Perry DJ; Kasdorf H; Van Echo DA
Cancer Treat Rep; 1984 Apr; 68(4):687-8. PubMed ID: 6713424
[No Abstract] [Full Text] [Related]
15. Phase II evaluation of dianhydrogalactitol in lung cancer: a Southwest Oncology Group Study.
Haas CD; Baker L; Thigpen T
Cancer Treat Rep; 1981; 65(1-2):115-7. PubMed ID: 6261943
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of pyrazofurin in patients with carcinoma of the lung.
Gralla RJ; Currie VE; Wittes RE; Golbey RB; Young CW
Cancer Treat Rep; 1978 Mar; 62(3):451-2. PubMed ID: 348315
[No Abstract] [Full Text] [Related]
17. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
Alberts DS; Mackel C; Pocelinko R; Salmon SE
Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
[TBL] [Abstract][Full Text] [Related]
18. [Polychemotherapy of small-cell bronchopulmonary cancer. The advantages of adding the selective cytostatic Riaval].
Păunescu E; Dănălache-Dumitrescu M; Oprişiu G; Smărăndache M; Stoinescu M; Vasile DI; Zaharescu C; Burnea D; Claiciu I; Ghinescu V
Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1986; 35(3):233-42. PubMed ID: 3027860
[No Abstract] [Full Text] [Related]
19. [Treatment of patients with lung cancer with a combination of nitrosomethylurea and cyclophosphane].
Perevodchikova NI; Korman NP; Bychkov MB
Vopr Onkol; 1975; 21(8):21-5. PubMed ID: 170742
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of bisantrene in previously treated patients with ovarian carcinoma: a Southwest Oncology Group Study.
Cowan JD; Surwit EA; Alberts DS; Boutselis JG; Neilan BA
Cancer Treat Rep; 1986 Mar; 70(3):423-4. PubMed ID: 3955558
[No Abstract] [Full Text] [Related]
[Next] [New Search]
